查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1587809

白细胞介素抑制剂市场规模、份额、趋势分析报告：按类型、给药途径、应用、最终用途、地区和细分市场预测，2025-2030 年

Interleukin Inhibitors Market Size, Share & Trends Analysis Report By Type, By Route Of Administration (SC, IV), By Application (RA, Psoriasis, IBD, Asthma), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

白细胞介素抑制剂市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球白细胞介素抑制剂市场规模将达到722亿美元，2025年至2030年复合年增长率为17.3%。

这背后是计划推出的强大后期管线药物。

该市场的治疗情势竞争日益激烈，目前正在透过头对头试验对药物进行比较，以确定其在安全性、有效性和耐受性方面的优越性。例如，UCB的bimekizumab目前正在针对Humira（研究名称：BE SURE）、 Stelara （BE VIVID）和Cosentyx（BE RADIANT）进行三项针对斑块型干癣的临床试验。

此外，增加对各种临床试验的投资以及製药公司和研究机构开发新分子的策略联盟是促进白细胞介素抑制剂市场成长的主要因素之一。例如，基因泰克（F. Hoffmann-La Roche）正在与马萨诸塞州总医院合作开发Actemra（托珠单抗），一种治疗鉅细胞动脉炎的药物。

消费者对各种自体免疫疾病及其治疗方案的认识不断提高预计将推动需求。例如，爱尔兰关节炎协会发起了一场类风湿性关节炎宣传活动，教育大众了解不同的治疗方案和早期诊断的价值。欧洲克隆氏症症和溃疡性大肠炎协会联合会也在努力提高人们对发炎性肠道疾病(IBD) 患者的认识。

白细胞介素抑制剂市场报告亮点

  • 从应用来看，干癣领域领先市场，到2024年将占37.0%的份额。
  • 到2024年，IL-23抑制剂将凭藉其在治疗干癣和IBD等自体免疫疾病的有效性，以27.5%的销售份额引领市场。
  • 按类型划分，IL-17 抑制剂在预测期内的复合年增长率预计将达到 16.1%。
  • 由于医疗基础设施的改善和可支配收入的增加，预计亚太地区在预测期内将出现最快的成长。
  • 儘管 IL 抑制剂价格昂贵，但有利的报销政策可能会使它们变得负担得起并提高市场渗透率。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章白细胞介素介素抑制剂市场变数、趋势、范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章白细胞介素抑制剂市场：按类型分类的业务分析

  • 2024 年和 2030 年按类型分類的市场占有率
  • 类型细分仪表板
  • 2018-2030 年按类型分類的市场规模、预测与趋势分析
  • IL-1抑制剂
  • IL-2抑制剂
  • IL-5抑制剂
  • IL-6抑制剂
  • IL-17抑制剂
  • IL-23抑制剂
  • 其他的

第五章白细胞介素抑制剂市场：给药途径的业务分析

  • 2024 年及 2030市场占有率给药途径途径
  • 途径细分仪表板
  • 2018-2030 年按管理途径的市场规模、预测与趋势分析
  • 皮下注射（SC）
  • 静脉注射 (IV)

第六章白细胞介素抑制剂市场：应用业务分析

  • 2024年及2030年应用市场占有率
  • 使用细分仪表板
  • 2018-2030 年按应用分類的市场规模、预测与趋势分析
  • 类风湿性关节炎
  • 干癣
  • 发炎性肠道疾病（IBD）
  • 气喘
  • 其他的

第七章白细胞介素抑制剂市场：最终用途业务分析

  • 2024 年及 2030 年最终用途市场占有率
  • 最终用途细分仪表板
  • 2018-2030 年按最终用途分類的市场规模、预测与趋势分析
  • 医院
  • 专科诊所
  • 其他的

第八章白细胞介素抑制剂市场：按类型、给药途径、应用和最终用途的区域估计和趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 按国家/地区划分，2018-2030
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 按国家/地区划分，2018-2030
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 按国家/地区划分，2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 按国家/地区划分，2018-2030
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 按国家/地区划分，2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章 竞争格局

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • Regeneron Pharmaceuticals Inc.
    • Johnson &Johnson Services, Inc.
    • F. Hoffmann-La Roche Ltd
    • AstraZeneca
    • Bausch Health Companies Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd
Product Code: GVR-3-68038-172-6

Interleukin Inhibitors Market Growth & Trends:

The global interleukin inhibitors market size is expected to reach USD 72.2 billion by 2030, registering a CAGR of 17.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to a strong pipeline with upcoming launches of late-stage pipeline drugs.

The therapeutic landscape in this market is becoming increasingly competitive, as drugs are compared in head-to-head trials to determine superiority in terms of safety, efficacy, and tolerance. For instance, UCB's bimekizumab is currently under investigation in three such trials against Humira (trial name: BE SURE), Stelara (BE VIVID), and Cosentyx (BE RADIANT)-indicated for plaque psoriasis.

Furthermore, increasing investments on various clinical trials and strategic alliances between pharmaceutical companies and research organizations for development of novel molecules are few major contributors to interleukin inhibitors market growth. For instance, Genentech (F. Hoffmann-La Roche Ltd.) has collaborated with Massachusetts General Hospital for developing Actemra (tocilizumab) for the treatment of giant cell arteritis.

Rise in consumer awareness about various autoimmune diseases and their treatment options is anticipated to impel demand. For instance, Arthritis Ireland launched an awareness campaign for rheumatoid arthritis, educating the public about different treatment options and significance of early diagnosis. In addition, the European Federation of Crohn's & Ulcerative Colitis Association offers various initiatives to create awareness among patients suffering from Inflammatory Bowel Disease (IBD).

Interleukin Inhibitors Market Report Highlights:

  • By application, the psoriatic segment leading the market and accounted for a share of 37.0% in 2024
  • In 2024, IL-23 inhibitors led the market with a revenue share of 27.5%, due to their efficacy in treating autoimmune diseases, such as psoriasis and IBD.
  • By type, IL-17 inhibitors are expected to witness a significant CAGR of 16.1% over the forecast period.
  • Asia Pacific is expected to exhibit the fastest regional growth over the forecast period, fueled by enhanced healthcare infrastructure and growing disposable incomes.
  • Despite the high price of IL-inhibitors, favorable reimbursement policies are likely to provide affordability and support market penetration.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Interleukin Inhibitors Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Interleukin Inhibitors Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. IL-1 Inhibitors
    • 4.4.1. IL-1 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.5. IL-2 Inhibitors
    • 4.5.1. IL-2 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.6. IL-5 Inhibitors
    • 4.6.1. IL-5 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.7. IL-6 Inhibitors
    • 4.7.1. IL-6 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.8. IL-17 Inhibitors
    • 4.8.1. IL-17 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.9. IL-23 Inhibitors
    • 4.9.1. IL-23 Inhibitors Market, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Interleukin Inhibitors Market: Route of Administration Business Analysis

  • 5.1. Route of Administration Market Share, 2024 & 2030
  • 5.2. Route of Administration Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Subcutaneous (SC)
    • 5.4.1. Subcutaneous (SC) Market, 2018 - 2030 (USD Million)
  • 5.5. Intravenous (IV)
    • 5.5.1. Intravenous (IV) Market, 2018 - 2030 (USD Million)

Chapter 6. Interleukin Inhibitors Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Rheumatoid Arthritis
    • 6.4.1. Rheumatoid Arthritis Market, 2018 - 2030 (USD Million)
  • 6.5. Psoriasis
    • 6.5.1. Psoriasis Market, 2018 - 2030 (USD Million)
  • 6.6. Inflammatory Bowel Disease (IBD)
    • 6.6.1. Inflammatory Bowel Disease (IBD) Market, 2018 - 2030 (USD Million)
  • 6.7. Asthma
    • 6.7.1. Asthma Market, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Interleukin Inhibitors Market: End Use Business Analysis

  • 7.1. End Use Market Share, 2024 & 2030
  • 7.2. End Use Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 7.5. Specialty Clinics
    • 7.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. Interleukin Inhibitors Market: Regional Estimates & Trend Analysis by Type, Route of Administration, Application, and End Use

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Interleukin Inhibitors Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Interleukin Inhibitors Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novartis AG
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. AbbVie Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Eli Lilly and Company
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Regeneron Pharmaceuticals Inc.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Johnson & Johnson Services, Inc.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. F. Hoffmann-La Roche Ltd
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AstraZeneca
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Bausch Health Companies Inc.
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. GlaxoSmithKline plc
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Teva Pharmaceutical Industries Ltd
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global interleukin inhibitors market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global interleukin inhibitors market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 Global interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 Global interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 North America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 8 North America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 9 North America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 North America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 11 North America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 U.S. interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 13 U.S. interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 U.S. interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.S. interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 16 Canada interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 17 Canada interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Canada interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 19 Canada interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Mexico interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 21 Mexico interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Mexico interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 23 Mexico interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Europe interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 25 Europe interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 26 Europe interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 28 Europe interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 29 UK interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 30 UK interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 UK interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 32 UK interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 33 Germany interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 34 Germany interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Germany interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 36 Germany interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 France interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 38 France interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 France interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 40 France interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 Italy interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 42 Italy interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Italy interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 44 Italy interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 Denmark interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 46 Denmark interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Denmark interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 48 Denmark interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Spain interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 50 Spain interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Spain interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 52 Spain interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 Sweden interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 54 Sweden interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 Sweden interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 56 Sweden interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 Norway interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 58 Norway interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 59 Norway interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 60 Norway interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Asia Pacific interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 62 Asia Pacific interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 63 Asia Pacific interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Asia Pacific interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 65 Asia Pacific interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 66 Japan interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 67 Japan interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Japan interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 69 Japan interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 70 China interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 71 China interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 China interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 73 China interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 74 India interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 75 India interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 India interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 77 India interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 78 Australia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 79 Australia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Australia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 81 Australia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 South Korea interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 83 South Korea interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 South Korea interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Korea interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Thailand interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 87 Thailand interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 Thailand interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 89 Thailand interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Latin America interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 91 Latin America interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 92 Latin America interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Latin America interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 94 Latin America interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 95 Brazil interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 96 Brazil interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Brazil interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 98 Brazil interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 99 Argentina interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 100 Argentina interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 101 Argentina interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 102 Argentina interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 Middle East & Africa interleukin inhibitors market, by country, 2018 - 2030 (USD Million)
  • Table 104 Middle East & Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 105 Middle East & Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 Middle East & Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 107 Middle East & Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 108 South Africa interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 109 South Africa interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 South Africa interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 111 South Africa interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 112 Saudi Arabia interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 113 Saudi Arabia interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Saudi Arabia interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 115 Saudi Arabia interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 116 UAE interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 117 UAE interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 UAE interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 119 UAE interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 120 Kuwait interleukin inhibitors market, by type, 2018 - 2030 (USD Million)
  • Table 121 Kuwait interleukin inhibitors market, by route of administration, 2018 - 2030 (USD Million)
  • Table 122 Kuwait interleukin inhibitors market, by application, 2018 - 2030 (USD Million)
  • Table 123 Kuwait interleukin inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Interleukin inhibitors market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Segment outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Interleukin inhibitors market dynamics
  • Fig. 13 Interleukin inhibitors market: Porter's five forces analysis
  • Fig. 14 Interleukin inhibitors market: PESTLE analysis
  • Fig. 15 Interleukin inhibitors market: Type segment dashboard
  • Fig. 16 Interleukin inhibitors market: Type market share analysis, 2024 & 2030
  • Fig. 17 IL-1 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 18 IL-2 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 19 IL-5 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 20 IL-6 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 21 IL-17 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 22 IL-23 inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Interleukin inhibitors market: Route of administration segment dashboard
  • Fig. 25 Interleukin inhibitors market: Route of administration market share analysis, 2024 & 2030
  • Fig. 26 Subcutaneous (SC) market, 2018 - 2030 (USD Million)
  • Fig. 27 Intravenous (IV) market, 2018 - 2030 (USD Million)
  • Fig. 28 Interleukin inhibitors market: Application segment dashboard
  • Fig. 29 Interleukin inhibitors market: Application market share analysis, 2024 & 2030
  • Fig. 30 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
  • Fig. 31 Psoriasis market, 2018 - 2030 (USD Million)
  • Fig. 32 Inflammatory bowel disease (IBD) market, 2018 - 2030 (USD Million)
  • Fig. 33 Asthma market, 2018 - 2030 (USD Million)
  • Fig. 34 Others market, 2018 - 2030 (USD Million)
  • Fig. 35 Interleukin inhibitors market: End use segment dashboard
  • Fig. 36 Interleukin inhibitors market: End use market share analysis, 2024 & 2030
  • Fig. 37 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 38 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 39 Others market, 2018 - 2030 (USD Million)
  • Fig. 40 Interleukin inhibitors market revenue, by region
  • Fig. 41 Regional marketplace: Key takeaways
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. country dynamics
  • Fig. 45 U.S. interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 46 Canada country dynamics
  • Fig. 47 Canada interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico country dynamics
  • Fig. 49 Mexico interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 51 UK country dynamics
  • Fig. 52 UK interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 53 Germany country dynamics
  • Fig. 54 Germany interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 55 France country dynamics
  • Fig. 56 France interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 57 Italy country dynamics
  • Fig. 58 Italy interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 59 Spain country dynamics
  • Fig. 60 Spain interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 61 Norway country dynamics
  • Fig. 62 Norway interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden country dynamics
  • Fig. 64 Sweden interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 65 Denmark country dynamics
  • Fig. 66 Denmark interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 68 Japan country dynamics
  • Fig. 69 Japan interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 70 China country dynamics
  • Fig. 71 China interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 72 India country dynamics
  • Fig. 73 India interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 74 Australia country dynamics
  • Fig. 75 Australia interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea country dynamics
  • Fig. 77 South Korea interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand country dynamics
  • Fig. 79 Thailand interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil country dynamics
  • Fig. 82 Brazil interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina country dynamics
  • Fig. 84 Argentina interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 85 MEA interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa country dynamics
  • Fig. 87 South Africa interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia country dynamics
  • Fig. 89 Saudi Arabia interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 90 UAE country dynamics
  • Fig. 91 UAE interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait country dynamics
  • Fig. 93 Kuwait interleukin inhibitors market, 2018 - 2030 (USD Million)
  • Fig. 94 Company categorization
  • Fig. 95 Company market position analysis
  • Fig. 96 Strategic framework